Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, William G. Wierda, MD PhD, Jason A. Dubovsky, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Alan Mitchell, MSc, Jerill Thorpe, BSc, Lin Yang, PhD, Kathleen A. Dorritie, MD

Blood (2018) 132 (Supplement 1): 300.

https://doi.org/10.1182/blood-2018-99-110462

Published: 2018

Journal Articles

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Blood (2015) 126 (23): 2979.

https://doi.org/10.1182/blood.V126.23.2979.2979

Published: 2015

Journal Articles

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

James E McDonald, Marcus M Kessler, Michael Gardner, Amy Buros, PhD, Sarah Waheed, MD, James Ntambi, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Nathan Petty, MS, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Alan Mitchell, Antje Hoering, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 724.

https://doi.org/10.1182/blood.V126.23.724.724

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Shmuel Yaccoby, Joshua Epstein, DSc, Pingping Qu, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Faith E Davies, MD, Alan Mitchell, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1808.

https://doi.org/10.1182/blood.V126.23.1808.1808

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Curing Multiple Myeloma (MM) with Total Therapy (TT)

Bart Barlogie, MD PhD, Alan Mitchell, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Antje Hoering, PhD, Gareth J. Morgan, MD PhD, John Crowley, PhD

Blood (2014) 124 (21): 195.

https://doi.org/10.1182/blood.V124.21.195.195

Published: 2014

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Alan Mitchell, Donald Johann, MD MS, Kelly Robbins, Ryan K Van Laar, PhD, Siraj Ali, MDPhD, Vincent A. Miller, MD, Clyde Bailey, Jeffery Sawyer, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 4775.

https://doi.org/10.1182/blood.V124.21.4775.4775

Published: 2014

Journal Articles

Curing myeloma at last: defining criteria and providing the evidence

Bart Barlogie, Alan Mitchell, Frits van Rhee, Joshua Epstein, Gareth J. Morgan, John Crowley

Blood (2014) 124 (20): 3043–3051.

https://doi.org/10.1182/blood-2014-07-552059

Published: 2014

Includes: Supplemental data

Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 126.

https://doi.org/10.1182/blood.V122.21.126.126

Published: 2013

Journal Articles

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Saad Z. Usmani, Alan Mitchell, Sarah Waheed, John Crowley, Antje Hoering, Nathan Petty, Tracy Brown, Twyla Bartel, Elias Anaissie, Frits van Rhee, Bart Barlogie

Blood (2013) 121 (10): 1819–1823.

https://doi.org/10.1182/blood-2012-08-451690

Published: 2013

Includes: Supplemental data

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

Journal Articles

Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5

Frits van Rhee, MD, PhD, Jeffrey R Sawyer, Ph.D., Saad Z Usmani, MD FACP, Sarah Waheed, MD, Christoph Heuck, MD, Alan Mitchell, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 193.

https://doi.org/10.1182/blood.V120.21.193.193

Published: 2012

Journal Articles

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, PhD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, John Crowley, PhD, Nathan M Petty, Stephen Harding, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 3976.

https://doi.org/10.1182/blood.V120.21.3976.3976

Published: 2012

Journal Articles

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Saad Z Usmani, MD FACP, Sarah Waheed, MD, Alan Mitchell, John Crowley, PhD, Antje Hoering, Nathan M Petty, Joshua Epstein, DSc, Christoph Heuck, MD, Shmuel Yaccoby, PhD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2012) 120 (21): 2910.

https://doi.org/10.1182/blood.V120.21.2910.2910

Published: 2012

Journal Articles

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Saad Usmani, MD, FACP, Alan Mitchell, Bijay Nair, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3081.

https://doi.org/10.1182/blood.V118.21.3081.3081

Published: 2011

Journal Articles

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Saad Usmani, MD, FACP, Alan Mitchell, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3082.

https://doi.org/10.1182/blood.V118.21.3082.3082

Published: 2011

Journal Articles

Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients

Antje Hoering, PhD, Alan Mitchell, Rachael Sexton, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1342.

https://doi.org/10.1182/blood.V116.21.1342.1342

Published: 2010

Journal Articles

Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

Alan Mitchell, Antje Hoering, PhD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1354.

https://doi.org/10.1182/blood.V116.21.1354.1354

Published: 2010

NARROW

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma

Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Curing Multiple Myeloma (MM) with Total Therapy (TT)

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Curing myeloma at last: defining criteria and providing the evidence

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients

Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only